GINS2 and central nervous system cancer: In this study, we performed ex vivo experiments to discover that GINS2 regulated the malignant phenotype and TMZ sensitivity of glioma cells, likely by promoting DDR through the early growth response protein 1 (EGR1)/ECT2 axis.